Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

This is a multi-center, prospective, single-arm, non-randomized, interventional phase II study of CML patients in first or second chronic phase (i.e. after allogeneic stem cell transplantation) and proven BCR::ABL1 T315I mutation. All patients will be treated with asciminib 200 mg BID. 50 patients will be enrolled from approximately 20 study sites in Germany.

Trial Details

NCT ID
NCT07789574
Phase
PHASE2
Sponsor
Thomas Ernst, Prof. Dr. med.
Status
RECRUITING
Cancer Type
Chronic Myeloid (CML) Leukemia
Interventions
  • asciminib 200 mg BID
Locations (sample)
  • Aachen, Germany|50.77664,6.08342
  • Berlin, Germany|52.52437,13.41053
  • Chemnitz, Germany|50.8357,12.92922
  • Dresden, Germany|51.05089,13.73832
  • Hamburg, Germany|53.55073,9.99302

Key Eligibility Criteria

  • Male or female patients with BCR::ABL1 positive CML in first or second chronic phase (i.e. after allogeneic stem cell transplantation) and proven T…
  • Age ≥ 18 years old (no upper age limit is given)
  • ECOG performance status of ≤2.
  • Serum levels of potassium, magnesium, total calcium within the normal limits (≥LLN \[lower limit of normal\] and ≤ULN \[upper limit of normal\]). C…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Myeloid (CML) Leukemia Trials on Trialify →